Sandoz’s High-Concentration Humira Biosimilar Lands On FDA’s Desk
SBLA Follows EMA Accepting Proposed Biosimilar For Filing In June
Sandoz has named its three most promising upcoming biosimilar launches, ahead of filing its proposed high-concentration version of adalimumab with the US Food and Drug Administration.
